SEC and FTC open two more investigations into Biogen's controversial Alzheimer's drug approval and marketing practices
Following Biogen’s announcement of miniscule 2021 sales for its controversial new Alzheimer’s drug yesterday, the company also revealed that the Federal Trade Commission and the Securities and Exchange Commission have opened two new, separate investigations into the troubled biotech.
The FTC, an antitrust regulator, has requested documents related to a civil investigative demand, similar to a subpoena, on the marketing and approval of the Alzheimer’s drug.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.